FMP

FMP

Enter

ARDX - Ardelyx, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ARDX.png

Ardelyx, Inc.

ARDX

NASDAQ

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

5.32 USD

-0.1 (-1.88%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

7.57M

10.1M

52.16M

124.46M

333.62M

611.65M

1.12B

2.06B

3.77B

6.91B

Revenue %

-

33.36

416.57

138.61

168.06

83.34

83.34

83.34

83.34

Operating Cash Flow

-81.44M

-152.55M

-70.04M

-89.72M

-44.81M

-471.61M

-864.65M

-1.59B

-2.91B

-5.33B

Operating Cash Flow %

-1.08k

-1.51k

-134.29

-72.09

-13.43

-77.1

-77.1

-77.1

-77.1

Cap Ex

-324k

-1.87M

-55k

-344k

-1.01M

-28.69M

-52.61M

-96.45M

-176.83M

-324.2M

Cap Ex %

-4.28

-18.49

-0.11

-0.28

-0.3

-4.69

-4.69

-4.69

-4.69

Free Cash Flow

-81.76M

-154.42M

-70.1M

-90.06M

-45.82M

-500.3M

-917.26M

-1.68B

-3.08B

-5.65B

Weighted Average Cost Of Capital

Price

5.32

Beta

Diluted Shares Outstanding

235.23M

Costof Debt

13.1

Tax Rate

After Tax Cost Of Debt

13.1

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

153.44M

Total Equity

1.25B

Total Capital

1.4B

Debt Weighting

10.92

Equity Weighting

89.08

Wacc

8.71

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

7.57M

10.1M

52.16M

124.46M

333.62M

611.65M

1.12B

2.06B

3.77B

6.91B

Operating Cash Flow

-81.44M

-152.55M

-70.04M

-89.72M

-44.81M

-471.61M

-864.65M

-1.59B

-2.91B

-5.33B

Cap Ex

-324k

-1.87M

-55k

-344k

-1.01M

-28.69M

-52.61M

-96.45M

-176.83M

-324.2M

Free Cash Flow

-81.76M

-154.42M

-70.1M

-90.06M

-45.82M

-500.3M

-917.26M

-1.68B

-3.08B

-5.65B

Wacc

8.71

8.71

8.71

8.71

8.71

Pv Lfcf

-460.22M

-776.17M

-1.31B

-2.21B

-3.72B

Sum Pv Lfcf

-8.48B

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

8.71

Free Cash Flow T1

-5.77B

Terminal Value

-85.94B

Present Terminal Value

-56.6B

Intrinsic Value

Enterprise Value

-65.08B

Net Debt

88.51M

Equity Value

-65.17B

Diluted Shares Outstanding

235.23M

Equity Value Per Share

-277.04

Projected DCF

-277.04 1.019%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep